Medikaloka Hermina PT (HEAL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medikaloka Hermina PT (HEAL) has a cash flow conversion efficiency ratio of 0.032x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp225.37 Billion ≈ $13.21 Million USD) by net assets (Rp7.01 Trillion ≈ $410.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medikaloka Hermina PT - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Medikaloka Hermina PT's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Medikaloka Hermina PT balance sheet liabilities for a breakdown of total debt and financial obligations.
Medikaloka Hermina PT Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medikaloka Hermina PT ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Turk Tuborg Bira ve Malt Sanayi AS
IS:TBORG
|
0.034x |
|
Dazhong Transportation Group Co Ltd A
SHG:600611
|
0.028x |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
1.464x |
|
Zhejiang Taitan Co Ltd
SHE:003036
|
0.018x |
|
Helia Group Ltd
AU:HLI
|
0.027x |
|
Paradise Co. Ltd
KQ:034230
|
0.028x |
|
Zhongtong Bus Holding Co Ltd
SHE:000957
|
0.118x |
|
Sinar Mas Agro Resources and Technology Tbk PT
JK:SMAR
|
0.103x |
Annual Cash Flow Conversion Efficiency for Medikaloka Hermina PT (2015–2024)
The table below shows the annual cash flow conversion efficiency of Medikaloka Hermina PT from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Medikaloka Hermina PT (HEAL) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rp5.87 Trillion ≈ $343.74 Million |
Rp1.14 Trillion ≈ $66.66 Million |
0.194x | -23.61% |
| 2023-12-31 | Rp5.20 Trillion ≈ $304.60 Million |
Rp1.32 Trillion ≈ $77.33 Million |
0.254x | +136.20% |
| 2022-12-31 | Rp4.69 Trillion ≈ $274.55 Million |
Rp503.58 Billion ≈ $29.51 Million |
0.107x | -74.60% |
| 2021-12-31 | Rp4.39 Trillion ≈ $257.02 Million |
Rp1.86 Trillion ≈ $108.77 Million |
0.423x | +27.07% |
| 2020-12-31 | Rp3.38 Trillion ≈ $198.18 Million |
Rp1.13 Trillion ≈ $66.01 Million |
0.333x | +60.80% |
| 2019-12-31 | Rp2.76 Trillion ≈ $161.98 Million |
Rp572.58 Billion ≈ $33.55 Million |
0.207x | +103.10% |
| 2018-12-31 | Rp2.37 Trillion ≈ $138.86 Million |
Rp241.67 Billion ≈ $14.16 Million |
0.102x | -79.03% |
| 2017-12-31 | Rp956.53 Billion ≈ $56.05 Million |
Rp465.08 Billion ≈ $27.25 Million |
0.486x | +68.84% |
| 2016-12-31 | Rp1.26 Trillion ≈ $73.83 Million |
Rp362.85 Billion ≈ $21.26 Million |
0.288x | +7.84% |
| 2015-12-31 | Rp957.59 Billion ≈ $56.11 Million |
Rp255.71 Billion ≈ $14.98 Million |
0.267x | -- |
About Medikaloka Hermina PT
PT Medikaloka Hermina Tbk, together with its subsidiaries, operates a network of hospitals in Indonesia. The company offers services in the areas of medical acupuncture, pediatrics, surgery, orthopedic surgery, plastic and reconstructive surgery, emergency medicine, forensic and medicolegal, dentistry, clinical nutrition, integrative medicine, cardiology, obstetrics and gynecology, nuclear medici… Read more